BODITECH MED INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15,900 KRW | -0.38% |
|
+7.36% | -22.44% |
| Sales 2024 * | 149B 108M | Sales 2025 * | 183B 133M | Capitalization | 349B 254M |
|---|---|---|---|---|---|
| Net income 2024 * | 32B 23.26M | Net income 2025 * | 39B 28.35M | EV / Sales 2024 * | 1.85 x |
| Net cash position 2024 * | 73B 53.07M | Net cash position 2025 * | 85B 61.8M | EV / Sales 2025 * | 1.44 x |
| P/E ratio 2024 * |
11.8
x | P/E ratio 2025 * |
9.58
x | Employees | 457 |
| Yield 2024 * |
0.94% | Yield 2025 * |
0.94% | Free-Float | 59.1% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.38% | ||
| 1 week | +7.36% | ||
| Current month | +11.74% | ||
| 1 month | +12.61% | ||
| 3 months | -8.30% | ||
| 6 months | -3.93% | ||
| Current year | -22.44% |
1 week
14 840.00
16 250.00
1 month
13 400.0016 250.00
Current year
13 400.0020 850.00
1 year
11 270.0022 150.00
3 years
8 420.0026 800.00
5 years
7 610.0039 700.00
10 years
7 610.0058 181.82
| Managers | Title | Age | Since |
|---|---|---|---|
Ui-Yeol Choe
CEO | Chief Executive Officer | 63 | 97-12-31 |
Ki-Bong Nam
CTO | Chief Tech/Sci/R&D Officer | 68 | 08-12-31 |
Yong-Hwan Byeon
BRD | Director/Board Member | 69 | 15-07-27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ui-Yeol Choe
CEO | Chief Executive Officer | 63 | 97-12-31 |
Kang-Oh Kim
BRD | Director/Board Member | 51 | 16-12-31 |
Ki-Bong Nam
CTO | Chief Tech/Sci/R&D Officer | 68 | 08-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 15,900 | -0.38% | 122,671 |
| 24-04-25 | 15,960 | +2.90% | 164,714 |
| 24-04-24 | 15,510 | +3.33% | 144,179 |
| 24-04-23 | 15,010 | +1.15% | 88,283 |
| 24-04-22 | 14,840 | +0.20% | 127,726 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
Boditech Med Inc is a Korea-based company principally engaged in the manufacture and sale of medical equipment. The Company is engaged in the manufacture and sale of antigen diagnostic kits and other products. In addition, the Company is engaged in the manufacture and sale of cancer diagnostic kit, drug concentration diagnostic kit and other products. The Company sells its products within domestic market and to overseas markets. The Company was established in 1998 and is located in Chuncheon-si, Gang-won-do, South Korea.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
15,900
KRW
Average target price
26,000
KRW
Spread / Average Target
+63.52%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -22.44% | 254M | |
| -12.91% | 19.08B | |
| -46.21% | 2.65B | |
| +18.15% | 1.87B | |
| -3.12% | 1.61B | |
| +23.78% | 1.21B | |
| -10.69% | 1.02B | |
| -20.89% | 905M | |
| -7.14% | 716M | |
| -18.10% | 682M |
- Stock Market
- Equities
- A206640 Stock
